Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FSHB8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,997
Award facts
- Contract value 100% obligated
- $13,996.86 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $13,996.86 to DMS Pharmaceutical Group Inc. for 68 mg Nexplanon implants on January 13, 2026, with completion expected by February 4, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.9 billion ceiling value through December 31, 2036.
The PPV-G GEN V contract represents a critical pharmaceutical supply vehicle supporting Department of Defense healthcare operations globally, enabling DLA to issue firm fixed-price delivery orders for branded and generic prescription medications, biologics, over-the-counter drugs, and medical consumables. DMS Pharmaceutical Group's established performance across numerous delivery orders and its comprehensive product portfolio, spanning oncology treatments, biologics, vaccines, contraceptive devices, and specialty pharmaceuticals, positions the company as a key regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FSHB8?
SPE2DR26FSHB8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26FSHB8 worth?
The government has obligated $13,997 on SPE2DR26FSHB8.
Is contract SPE2DR26FSHB8 an order under another contract?
Yes. SPE2DR26FSHB8 is a delivery order under SPE2DR25D9305, an indefinite delivery contract.
Was contract SPE2DR26FSHB8 competed?
The extent of competition for SPE2DR26FSHB8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award